Proinflammatory B-cell profile in the early phases of MS predicts an active disease
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received August 21, 2017
- Accepted in final form October 30, 2017
- First Published December 26, 2017.
Author Disclosures
- Thomas Guerrier, PhD,
- Myriam Labalette, MD, PhD,
- David Launay, MD, PhD,
- Catalina Lee-Chang, PhD,
- Olivier Outteryck, MD, PhD,
- Guillaume Lefèvre, MD, PhD,
- Patrick Vermersch, MD, PhD,
- Sylvain Dubucquoi, MD, PhD* and
- Hélène Zéphir, MD, PhD*
- Thomas Guerrier, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1)GENZYME
NONE
(1)Universit? Lille 2
(1)Fondation pour la Recherche (2)ARSEP
NONE
NONE
NONE
NONE
NONE
NONE
- Myriam Labalette, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- David Launay, MD, PhD,
Shire
NONE
Shire, GSK, CSL Behring, Pfizer
Revue de M?decine Interne, associate editor, 2002-ongoing
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Catalina Lee-Chang, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Olivier Outteryck, MD, PhD,
NONE
NONE
(1) Bayer Schering Pharma, funding for travel and speaker honoraria; (2) Biogen Idec, funding for travel and speaker honoraria; (3) Merck Serono, funding for travel; (4) Novartis, funding for travel and speaker honoraria (5) Sanofi-Aventis, funding for travel and speaker honoraria; (6) Teva Pharmaceutical Industries Ltd, funding for travel
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1)research grants from Biogen Idec and Novartis
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Guillaume Lefèvre, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Patrick Vermersch, MD, PhD,
Serves on scientific advisory boards for (1) Sanofi, (2) Biogen, (3) Merck, (4) Teva, (5) Novartis, (6) Roche, (7) Servier, (8) Celgene
NONE
(1) Biogen, travel and speaker honoraria; (2) Roche, travel and honoraria; (3) Novartis, honoraria; (4) Teva, travel and honoraria; (5) Sanofi-Aventis, honoraria; (6) Almirall, honoraria (6) Merck Serono, travel and honoraria (7) Celgene, travel and honoraria
Neurosciences et scl?rose en plaques
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Research support from (1) Biogen, (2) Novartis, (3) Merck, (4) Sanofi-Genzyme, (5) Roche
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sylvain Dubucquoi, MD, PhD* and
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Hélène Zéphir, MD, PhD*
NONE
NONE
NONE
NONE
NONE
NONE
NONE
I received consultancies fees from BIOGENIDEC, MERCK, BAYER, NOVARTIS, SANOFI, GENZYME, TEVA
NONE
NONE
NONE
I received research support grants from TEVA
NONE
I received research support grants from Ligue Fran?aise contre la scl?rose en plaques and from ARSEP (Association de recherche contre la Scl?rose en plaques)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Correspondence to Dr. Zéphir: helene.zephir{at}chru-lille.fr
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Topics Discussed
Alert Me
Recommended articles
-
What's Happening
What's happening in Neurology® Neuroimmunology & Neuroinflammationet al.Neurology, July 02, 2018 -
Article
B-Cell Compartmental Features and Molecular Basis for Therapy in Autoimmune DiseaseChao Zhang, Tian-Xiang Zhang, Ye Liu et al.Neurology: Neuroimmunology & Neuroinflammation, August 31, 2021 -
Article
Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MSJosé I. Fernández-Velasco, Jens Kuhle, Enric Monreal et al.Neurology: Neuroimmunology & Neuroinflammation, January 06, 2021 -
Article
Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsetsSteven K. Lundy, Qi Wu, Qin Wang et al.Neurology - Neuroimmunology Neuroinflammation, March 03, 2016